Gantenerumab fails; time for Roche to cut its Alzheimer's losses?
This article was originally published in Scrip
Executive Summary
Roche is dropping a Phase III trial of the anti-amyloid gantenerumab in prodromal Alzheimer's disease patients. The decision calls into question not only the future of this drug, but also that of other disease modifying anti-amyloids, including Roche's crenezumab.
You may also be interested in...
Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Brazilian Regulator Extends COVID-19 Measures
Brazil’s medicines regulator is extending COVID-19 era resolutions designed to speed up its evaluation of clinical research in Brazil.
Canada Publishes Real World Evidence Guidance For HTA And Regulatory Decision Making
The new guidance was drawn up through extensive engagement with national and international experts in RWD and RWE, as well as stakeholders in Canada.